2 results match your criteria: "Dana-Farber Harvard Cancer Centre[Affiliation]"
Enrichment of Bacteroides fragilis and enterotoxigenic Bacteroides fragilis in CpG island methylator phenotype-high colorectal carcinoma.
Clin Microbiol Infect
May 2024
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Cancer Immunology Program, Dana-Farber Harvard Cancer Centre, Boston, MA, USA. Electronic address:
Article Synopsis
- Research suggests that enterotoxigenic Bacteroides fragilis (ETBF) may play a role in colorectal cancer development, particularly in tumors with specific genetic markers like high-level CpG island methylator phenotype (CIMP-high) and BRAF mutations.
- The study utilized quantitative PCR to measure levels of Bacteroides fragilis and ETBF in colorectal cancer cases, finding that high levels of these bacteria are significantly linked to the presence of CIMP-high and MSI-high tumors.
- Overall, the results provide evidence that Bacteroides fragilis and ETBF may influence colorectal cancer progression through particular genetic pathways, although they do not appear to affect patient survival rates.
Immune-related tumour response assessment criteria: a comprehensive review.
Br J Radiol
April 2018
2 Department of Radiology, Massachusetts General Hospital, Boston, MA , USA.
Growing emphasis on precision medicine in oncology has led to increasing use of targeted therapies that encompass a spectrum of drug classes including angiogenesis inhibitors, immune modulators, signal transduction inhibitors, DNA damage modulators, hormonal agents etc. Immune therapeutic drugs constitute a unique group among the novel therapeutic agents that are transforming cancer treatment, and their use is rising. The imaging manifestations in patients on immune therapies appear to be distinct from those typically seen with conventional cytotoxic therapies.
View Article and Find Full Text PDF